Nama's AI scorecard currently rates Zoetis Buy (6.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ZTS's P/E ratio?

Zoetis trades at a trailing price-to-earnings ratio of 12.0.

When does ZTS report earnings?

Zoetis's next scheduled report is on Feb 11, 2027. Analysts expect EPS of $1.21.

What is the ZTS price target?

The median analyst price target from 13 analysts is $85.00, with a range of $74.00 – $115.00.

Is ZTS Shariah compliant?

Nama's AAOIFI-style screen reads Zoetis as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Does ZTS pay a dividend?

Yes — Zoetis's dividend yield is 2.7%.

Nama Insights

Zoetis (ZTS)

Healthcare · Drug Manufacturers Specialty Generic · NYSE

S&P 500

Zoetis (ZTS) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $32.81B, a trailing price-to-earnings ratio of 12.0 and a free-cash-flow yield of 6.5%. Over the most recent reported fiscal year, revenue grew 2.3% and free cash flow per share grew 1.8%. Nama's AI scorecard rates it Buy, 6.9 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Buy · 6.9/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Trailing · -40.1% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-68.2%

How far the last close sits under the highest price of the past five years.

Market cap	$32.81B
Trailing P/E	12.0
Price / book	10.4
Price / sales	3.4
FCF yield	6.5%
Dividend yield	2.7%
Gross margin	71.5%
Operating margin	37.6%
Net margin	27.5%
Revenue growth (YoY)	+2.3%
Revenue growth (3-yr annual)	+5.4%
EPS growth (YoY)	+8.4%
FCF/share growth (YoY)	+1.8%
Beta	0.7
Exchange	NYSE
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

ZTS earnings

Next report: Feb 11, 2027 (Q4 2026, EPS estimate $1.21). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$1.75	$1.51	+15.9%	$2.39B
Q2 2026	Aug 6, 2026	$1.87	$1.85	+1.1%	$2.47B
Q1 2026	May 7, 2026	$1.53	$1.62	-5.6%	$2.26B
Q4 2025	Feb 12, 2026	$1.48	$1.40	+5.7%	$2.39B

ZTS analyst price target

Median target $85.00 from 13 analysts, ranging $74.00 – $115.00.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
HLN	Haleon	$40.17B	21.3
UTHR	United Therapeutics	$23.94B	21.2
VTRS	Viatris	$22.87B	7.8
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3
RDY	Dr. Reddy's Laboratories	$12.43B	20.4

Explore live ZTS data on Nama Insights →

Recent Congressional trades

Zoetis trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Oct 12, 2026
Gilbert Cisneros	House	Sell	$1,001 - $15,000	Sep 4, 2026
Byron Donalds	House	Buy	$1,001 - $15,000	Jul 15, 2026
Byron Donalds	House	Buy	$1,001 - $15,000	Jul 15, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Jul 2, 2026
Gilbert Cisneros	House	Sell	$1,001 - $15,000	May 8, 2026
Gilbert Cisneros	House	Sell	$1,001 - $15,000	Apr 7, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Mar 9, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Jan 12, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Dec 15, 2025
Rick Larsen	House	Sell	$1,001 - $15,000	Oct 16, 2025
Gilbert Cisneros	House	Sell	$1,001 - $15,000	Sep 12, 2025

ZTS FAQ

Is ZTS a buy?: Nama's AI scorecard currently rates Zoetis Buy (6.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ZTS's P/E ratio?: Zoetis trades at a trailing price-to-earnings ratio of 12.0.
When does ZTS report earnings?: Zoetis's next scheduled report is on Feb 11, 2027. Analysts expect EPS of $1.21.
What is the ZTS price target?: The median analyst price target from 13 analysts is $85.00, with a range of $74.00 – $115.00.
Is ZTS Shariah compliant?: Nama's AAOIFI-style screen reads Zoetis as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.
Does ZTS pay a dividend?: Yes — Zoetis's dividend yield is 2.7%.